{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:56:35Z","timestamp":1793858195654,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105893","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T22:10:26Z","timestamp":1765491026000},"page":"105893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study"],"prefix":"10.1016","volume":"10","author":[{"given":"S.","family":"Kondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"N.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"E.","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yamamuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hayata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7531-2274","authenticated-orcid":false,"given":"T.","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2025.105893_bib1","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105893_bib2","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/emboj.2012.126","article-title":"Drugging Wnt signalling in cancer","volume":"31","author":"Polakis","year":"2012","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105893_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0081","article-title":"Canonical Wnt\/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance","volume":"3","author":"Watson","year":"2013","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105893_bib4","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105893_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3748\/wjg.v22.i2.823","article-title":"Targeting Wnt\/\u03b2-catenin pathway in hepatocellular carcinoma treatment","volume":"22","author":"Vilchez","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"7407","key":"10.1016\/j.esmoop.2025.105893_bib6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105893_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrclinonc.2016.19","article-title":"Evolving molecularly targeted therapies for advanced-stage thyroid cancers","volume":"13","author":"Bible","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105893_bib8","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2353\/ajpath.2008.080475","article-title":"Specific mutations in the \u03b2-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors","volume":"173","author":"Lazar","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.esmoop.2025.105893_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1442441","article-title":"The role of CTNNB1 in endometrial cancer","volume":"2022","author":"Ledinek","year":"2022","journal-title":"Dis Markers"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105893_bib10","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/0008-5472.CAN-20-0782","article-title":"E7386, a selective inhibitor of the interaction between \u03b2-catenin and CBP, exerts antitumor activity in tumor models with activated canonical Wnt signaling","volume":"81","author":"Yamada","year":"2021","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105893_bib11","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","article-title":"A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors","volume":"23","author":"Jimeno","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105893_bib12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10637-019-00824-1","article-title":"A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer","volume":"38","author":"Davis","year":"2020","journal-title":"Invest New Drugs"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105893_bib13","doi-asserted-by":"crossref","first-page":"S431","DOI":"10.1016\/S0168-8278(25)01237-1","article-title":"THU-077-YI E7386 enhances lenvatinib\u2019s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma","volume":"82","author":"Mesropian","year":"2025","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105893_bib14","article-title":"76 (PB064): E7386 enhances both lenvatinib and anti-PD1 antitumor activity in HCC","volume":"211","author":"Mesropian Badalian","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105893_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2025.105893_bib16","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105893_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1200\/JCO.24.00410","article-title":"DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy in advanced gastric or gastroesophageal junction adenocarcinoma: DisTinGuish","volume":"43","author":"Klempner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105893_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2023.03.013","article-title":"DKK1 is a predictive biomarker for response to DKN-01: results of a phase 2 basket study in women with recurrent endometrial carcinoma","volume":"172","author":"Arend","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105893_bib19","article-title":"Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor","volume":"40","author":"Cranmer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105893_bib20","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.3390\/ijms24076733","article-title":"Wnt signaling inhibitors and their promising role in tumor treatment","volume":"24","author":"Pe\u0107ina-\u0160laus","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2025.105893_bib22","article-title":"Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors","volume":"84","author":"Cook","year":"2024","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105893_bib23","article-title":"A phase 1\/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with \u03b2-catenin activating mutations","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105893_bib24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/bloodadvances.2019000757","article-title":"Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Lee","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105893_bib25","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.1200\/jco.2014.32.15_suppl.8068","article-title":"A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer","volume":"32","author":"Edenfield","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 10","key":"10.1016\/j.esmoop.2025.105893_bib26","article-title":"P2.06-11 A phase I\/II study of intrapleural ad-SGE-REIC administration in patients with refractory malignant pleural mesothelioma [abstract]","volume":"13","author":"Goto","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105893_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc2645","article-title":"Genetic prognostic and predictive markers in colorectal cancer","volume":"9","author":"Walther","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.105893_bib28","article-title":"738P Global, phase Ib dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO)","volume":"35","author":"Lee","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105893_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101812","article-title":"Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced\/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors","volume":"35","author":"Eskander","year":"2025","journal-title":"Int J Gynecol Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:01:48Z","timestamp":1773896508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017624"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105893","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Eisai Inc. and The Author(s).  Published by Elsevier Ltd. On behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105893"}}